Chase Sun Pharmaceutical's blood purification injection extends national insurance coverage

Tianjin Chase Sun Pharmaceutical Co., Ltd. announced that its Blood Purification Injection has successfully renewed its inclusion in the National Medical Insurance Drug Catalogue (2025 Edition). This renewal, based on negotiation results for 2026-2027, ensures the product remains covered.

The medical insurance payment standard is RMB 22.08 (10ml/vial), with access restricted to secondary and higher-level medical institutions. The agreement is effective from January 1, 2026, to December 31, 2027.

The company clarified that the new drug catalog's official implementation from January 1, 2026, means this renewal will not significantly impact the company's operating performance for the current reporting period.

Future sales performance of the drug is subject to uncertainties influenced by changes in healthcare industry policies and market conditions. Investors are advised to exercise caution in their decisions and be aware of investment risks.